Vacina previne lesões da vulva e da vagina potencialmente pré-cancerígenas

**20 541 women aged 16 to 26 years were enrolled in the combined analysis of four randomised double blind placebo controlled phase II and III studies and received in three studies 3 injections of the quadrivalent Human Papillomavirus (types 6, 11, 16, 18) vaccine at day 1, month 2 and month 6 of the study and in one study women received 3 injections of the monovalent Human Papillomavirus (type 16) at day 1, month 2 and month 6 of the study. At specific pre-determined times during the study the women were examined and tests carried out for the presence of Human Papillomavirus and cervical lesions. The women in the study have been followed for around 2 years following enrolment.
[Ault K, Prophylactic use of quadrivalent Human Papillomavirus (HPV) (types 6, 11, 16&18) L1virus- like particule (VLP) vaccine reduces cervical intraepithelial neoplasia (CIN) 2/3 and adenocarcinoma in situ (AIS) risk. Abstract presented at the European Cancer Conference (ECCO) November 2nd, 2005, Paris France]

***The aim of this phase III study was to investigate the efficacy of the quadrivalent Human Papillomavirus (type 6, 11, 16, 18) vaccine on all grades of cervical lesions and external genital lesions. 5455 women aged 16 to 23 years were enrolled in a randomised double blind placebo controlled study. They received 3 injections of the quadrivalent Human Papillomavirus (types 6, 11, 16, 18) vaccine at day 1, month 2 and month 6 of the study. At specific pre-determined times during the study the women were examined and tests carried out for the presence of Human Papillomavirus as well as cervical and external genital lesions. The women in the study have been followed for 2 years following enrolment.
[Sattler C et al. Efficacy and safety of a quadrivalent prophylactic Human Papillomavirus (types 6, 11, 16, 18) L1 virus like particle (VLP) vaccine for Prevention of Cervical Dysplasia and External Genital lesions(EGL).Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), December 16, 2005; Washington]

Sobre a Sanofi Pasteur MSD

A Sanofi Pasteur MSD é uma joint venture entre a Sanofi Pasteur, a divisão de vacinas da sanofi-aventis, e Merck & Co., Inc. Combinando a inovação com a perícia, a Sanofi Pasteur MSD é a única empresa na Europa dedicada exclusivamente às vacinas. Sanofi Pasteur MSD utiliza a experiência no campo da investigação da sanofi Pasteur e Merck & CO., Inc., juntamente com as suas equipas de todo o mundo, para focar no desenvolvimento de novas vacinas para a Europa, com a finalidade de alargar a protecção a outras doenças e aperfeiçoar as vacinas existentes por forma a melhorar a sua aceitabilidade, eficácia e tolerabilidade.

NULL

NULL

NULL

NULL

NULL